SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer

SIMPLE SUMMARY: The IMpassion130 trial suggests that metastatic triple-negative breast cancer (TNBC) patients with PD-L1+ derived a clinical benefit from atezolizumab-combined treatment regardless of the sample collection time or origin. Therefore, if the PD-L1 test is positive at least once in mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Baek, Seung Ho, Kim, Jee Hung, Bae, Soong June, Ji, Jung Hwan, Lee, Yangkyu, Jeong, Joon, Cha, Yoon Jin, Ahn, Sung Gwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265054/
https://www.ncbi.nlm.nih.gov/pubmed/35804813
http://dx.doi.org/10.3390/cancers14133042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265054/
https://www.ncbi.nlm.nih.gov/pubmed/35804813
http://dx.doi.org/10.3390/cancers14133042

Ejemplares similares